RxDoctor Payments Data

Srirengam Muralidhasan, MD

Family Medicine · Las Cruces, NMNPI 1902898257

Payments from drug & device makers

$789in general payments, 2019–2025

Across 43 payments — averaging $18.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$230
  • Novo Nordisk$90
  • GSK$84
  • AstraZeneca$75
  • Novartis$71
  • Sanofi-aventis U.S. LLC$45
  • plus $194 from 8 others

What the payments were for

  • Food & beverage$69388%
  • Education$9612%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$789 in reported general payments places this provider in the 75th percentile of 717 family medicine providers in New Mexico.

See all family medicine providers in New Mexico

Medicare billing

Part B allowed, 2024
$382,302
Medicare patients
684
Services billed
6,468

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide270$285,733
JardianceEmpagliflozin287$283,712
EliquisApixaban179$194,549
FarxigaDapagliflozin Propanediol136$117,365
Trelegy ElliptaFluticasone/Umeclidin/Vilanter115$84,994
TrulicityDulaglutide83$84,381
MounjaroTirzepatide51$57,224
JanuviaSitagliptin Phosphate50$42,368
XareltoRivaroxaban27$40,176
Breztri AerosphereBudesonide/Glycopyr/Formoterol52$35,838
Tresiba Flextouch U-200Insulin Degludec34$34,045
LinzessLinaclotide45$29,756
EntrestoSacubitril/Valsartan14$27,952
Combivent RespimatIpratropium/Albuterol Sulfate48$24,936
Lantus SolostarInsulin Glargine,hum.Rec.Anlog166$24,410

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$90$309,528282 claims
PfizerEliquis$12$194,549179 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$75$173,904255 claims
Lilly USA, LLCTrulicity, Mounjaro$26$141,605134 claims
GSKTrelegy Ellipta, Breo Ellipta$84$98,535135 claims
AbbVieLinzess$30$29,75645 claims
NovartisEntresto$71$27,95214 claims
Astellas Pharma US IncMyrbetriq$230$14,15715 claims
Sanofi-aventis U.S. LLCLantus$45$10,01840 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 717 family medicine providers in New Mexico.

Other family medicine in Las Cruces

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →